Investment Analysts’ Recent Ratings Changes for MiMedx Group (MDXG)

MiMedx Group (NASDAQ: MDXG) has recently received a number of price target changes and ratings updates:

• 2/28/2026 – MiMedx Group was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/23/2026 – MiMedx Group is now covered by Citigroup Inc.. They set a “market outperform” rating on the stock.
• 2/23/2026 – MiMedx Group was given a new $10.00 price target by UBS Group AG.
• 2/23/2026 – MiMedx Group is now covered by Citizens Jmp. They set a “market outperform” rating and a $10.00 price target on the stock.
• 2/17/2026 – MiMedx Group had its price target lowered by Cantor Fitzgerald from $12.00 to $8.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – MiMedx Group had its price target lowered by Lake Street Capital from $12.00 to $10.00. They now have a “buy” rating on the stock.

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.